Stocks
Biogen Financial Statements (BIIB) |
||||||||||
| Biogensmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 25.04.2023 | 25.07.2023 | 08.11.2023 | 13.02.2024 | 24.04.2024 | 24.04.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 2 463 | 2 456 | 2 530 | 2 386 | 2 200 | 9 573 | |||
| Operating Income, bln rub | 526.9 | 655.7 | -141.2 | 291.6 | 545.4 | 1 352 | ||||
| EBITDA, bln rub | ? | 577.1 | 708.6 | 371.7 | 623.2 | 693.0 | 2 397 | |||
| Net profit, bln rub | ? | 387.9 | 591.6 | -68.1 | 249.7 | 393.4 | 1 167 | |||
| OCF, bln rub | ? | 455.3 | 487.0 | 592.4 | 12.5 | 553.2 | 1 645 | |||
| CAPEX, bln rub | ? | 71.6 | 87.0 | 87.6 | 65.2 | 120.9 | 360.7 | |||
| FCF, bln rub | ? | 383.7 | 400.0 | 504.8 | -52.7 | 432.3 | 1 284 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 1 283 | 1 242 | 1 636 | 1 310 | 965.1 | 5 153 | ||||
| Cost of production, bln rub | 662.8 | 592.7 | 659.6 | 618.3 | 689.8 | 2 560 | ||||
| R&D, bln rub | 570.6 | 584.2 | 736.3 | 570.9 | 383.6 | 2 275 | ||||
| Interest expenses, bln rub | 62.5 | 49.1 | 63.8 | 71.5 | 69.2 | 253.6 | ||||
| Assets, bln rub | 24 598 | 25 157 | 28 193 | 26 845 | 26 568 | 26 568 | ||||
| Net Assets, bln rub | ? | 13 787 | 14 461 | 14 480 | 14 799 | 15 213 | 15 213 | |||
| Debt, bln rub | 6 610 | 6 589 | 7 715 | 7 338 | 6 947 | 6 947 | ||||
| Cash, bln rub | 5 041 | 6 078 | 2 288 | 1 050 | 1 074 | 1 074 | ||||
| Net debt, bln rub | 1 568 | 510.7 | 5 427 | 6 288 | 5 872 | 5 872 | ||||
| Ordinary share price, rub | 278.0 | 284.9 | 257.0 | 258.8 | 215.6 | 242.7 | ||||
| Number of ordinary shares, mln | 144.4 | 144.7 | 144.8 | 144.9 | 145.2 | 145.2 | ||||
| Market cap, bln rub | 40 148 | 41 218 | 37 215 | 37 496 | 31 309 | 35 246 | ||||
| EV, bln rub | ? | 41 716 | 41 728 | 42 642 | 43 784 | 37 182 | 41 118 | |||
| Book value, bln rub | 6 222 | 6 930 | 328 | 217 | 701 | 701 | ||||
| EPS, rub | ? | 2.69 | 4.09 | -0.47 | 1.72 | 2.71 | 8.03 | |||
| FCF/share, rub | 2.66 | 2.76 | 3.49 | -0.36 | 2.98 | 8.85 | ||||
| BV/share, rub | 43.1 | 47.9 | 2.26 | 1.50 | 4.83 | 4.83 | ||||
| EBITDA margin, % | ? | 23.4% | 28.9% | 14.7% | 26.1% | 31.5% | 25.0% | |||
| Net margin, % | ? | 15.7% | 24.1% | -2.69% | 10.5% | 17.9% | 12.2% | |||
| FCF yield, % | ? | 3.54% | 2.73% | 2.76% | 3.30% | 4.10% | 3.64% | |||
| ROE, % | ? | 22.7% | 18.4% | 10.1% | 7.85% | 7.67% | 7.67% | |||
| ROA, % | ? | 12.7% | 10.6% | 5.18% | 4.33% | 4.39% | 4.39% | |||
| P/E | ? | 12.8 | 15.5 | 25.5 | 32.3 | 26.8 | 30.2 | |||
| P/FCF | 28.3 | 36.7 | 36.3 | 30.3 | 24.4 | 27.4 | ||||
| P/S | ? | 3.97 | 4.13 | 3.72 | 3.81 | 3.27 | 3.68 | |||
| P/BV | ? | 6.45 | 5.95 | 113.6 | 172.6 | 44.7 | 50.3 | |||
| EV/EBITDA | ? | 13.4 | 15.1 | 19.6 | 19.2 | 15.5 | 17.2 | |||
| Debt/EBITDA | 0.51 | 0.18 | 2.50 | 2.76 | 2.45 | 2.45 | ||||
| R&D/CAPEX, % | 796.9% | 671.5% | 840.5% | 875.6% | 317.3% | 630.7% | ||||
| CAPEX/Revenue, % | 2.91% | 3.54% | 3.46% | 2.73% | 5.49% | 3.77% | ||||
| Biogen shareholders | ||||||||||
